title: Longitudinal treatment patterns among US patients with atherosclerotic cardiovascular disease or familial hypercholesterolemia initiating lipid-lowering pharmacotherapy.
abstract: The most recent American College of Cardiology-American Heart Association guidelines recommend high-dose statin therapy for most patients with confirmed atherosclerotic cardiovascular disease (ASCVD) and patients with high cardiovascular risk. There is limited information regarding long-term treatment patterns among these patients.
  
  
  
  To examine longitudinal treatment modifications in patients with ASCVD or familial hypercholesterolemia (FH).
  
  
  
  This retrospective analysis of administrative claims data identified patients initiating statin or ezetimibe therapy between January 1, 2007, and December 31, 2012, who had evidence of ASCVD or FH. Patients were followed for up to 3 years and up to 4 treatment episodes. After initial treatment, subsequent treatment episodes began on the date of a treatment modification, which included discontinuation, statin dose change, switching, and augmentation.
  
  
  
  A total of 92,621 patients (mean age 64.7 years, 57.3% male) were identified; 91,740 had ASCVD, 937 had FH (56 had both). Most ASCVD (89.6%) and FH (85.8%) patients initiated on statin monotherapy. The most common treatment modification in the first treatment episode was discontinuation (ASCVD: 42.0%; FH: 58.4%); among patients who discontinued, most reinitiated therapy (70.5% of ASCVD, 76.8% of FH). Most ASCVD (68.2%) and FH (71.1%) patients initiated on moderate-dose statins; statin dose increase occurred in 10.3% of ASCVD and 18.5% of FH patients in the first episode.
  
  
  
  Among patients with high cardiovascular risk, most initiated on moderate-dose statins with infrequent uptitration. In light of the recent American College of Cardiology-American Heart Association guidelines, statin initiation practices will need to change to ensure appropriate therapy for high-risk patients.
authors.affiliation: Health Economics and Outcomes Research, Optum, Inc, Eden Prairie, MN, USA. Electronic address: James.Burke@optum.com.
authors.forename: James P
authors.initials: JP
authors.lastname: Burke
authors.affiliation: Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
authors.forename: Ross J
authors.initials: RJ
authors.lastname: Simpson
authors.affiliation: Global Health Economics, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA, USA.
authors.forename: Carly J
authors.initials: CJ
authors.lastname: Paoli
authors.affiliation: Health Economics and Outcomes Research, Optum, Inc, Eden Prairie, MN, USA.
authors.forename: Jeffrey T
authors.initials: JT
authors.lastname: McPheeters
authors.affiliation: Global Health Economics, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA, USA.
authors.forename: Shravanthi R
authors.initials: SR
authors.lastname: Gandra
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002318:Cardiovascular Diseases / Q000150:complications / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D006938:Hyperlipoproteinemia Type II / Q000150:complications / Q000188:drug therapy*; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D014481:United States; D055815:Young Adult
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors
keywords: Familial hypercholesterolemia; High risk; High-dose statin; Treatment discontinuation; Treatment patterns; Treatment switching